PA
AZN icon

Procyon Advisors’s AstraZeneca AZN Stock Holding History

Procyon Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$53K – 281
2020
Q2 		$53K Buy
+500
New +$51.6K 0.03% 373

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Procyon Advisors's AZN Position: Q2 2026 in Review

Procyon Advisors reduced its AstraZeneca (AZN) stake by 2.9% in Q2 2026, selling an estimated $27.3K and leaving 4,845 shares worth $919K. The position accounts for 0.04% of the portfolio, ranked #286.

Procyon Advisors first reported a position in AZN in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.78M in Q1 2025. 585 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Procyon Advisors held 4,845 shares of AstraZeneca worth $919K as of Q2 2026.
  • Procyon Advisors sold 145 AstraZeneca shares in Q2 2026, an estimated $27.3K.
  • AstraZeneca made up 0.04% of Procyon Advisors's portfolio in Q2 2026, its #286 holding.
  • Procyon Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 27 quarters since.
  • Procyon Advisors's AstraZeneca position peaked at $2.78M in Q1 2025.
  • 585 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.